| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $24,088,725 | 25 | 100 |
| Waddill William D. | director | 0 | $0 | 4 | $1.69M | $-1.69M |
| MOLINA ARTURO MD | Chief Medical Officer | 0 | $0 | 8 | $5.75M | $-5.75M |
| Ali Asif | Chief Financial Officer | 0 | $0 | 4 | $6.09M | $-6.09M |
| PATEL DINESH V PH D | President and CEO | 0 | $0 | 9 | $10.56M | $-10.56M |
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Over the last 12 months, insiders at Protagonist Therapeutics, Inc. have bought $0 and sold $24.09M worth of Protagonist Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protagonist Therapeutics, Inc. have bought $0 and sold $11.16M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 24,000 shares for transaction amount of $160,800 was made by SELICK HAROLD E (director) on 2020‑03‑12.
| 2026-01-27 | Sale | PATEL DINESH V PH D | President and CEO | 4,068 0.0065% | $83.19 | $338,417 | +0.83% | |
| 2026-01-27 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 5,000 0.0079% | $82.00 | $410,000 | +0.83% | |
| 2026-01-27 | Sale | Ali Asif | Chief Financial Officer | 46,203 0.074% | $83.13 | $3.84M | +0.83% | |
| 2026-01-26 | Sale | PATEL DINESH V PH D | President and CEO | 24,890 0.0407% | $84.03 | $2.09M | +0.09% | |
| 2026-01-26 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 5,000 0.008% | $82.28 | $411,400 | +0.09% | |
| 2026-01-23 | Sale | PATEL DINESH V PH D | President and CEO | 19,315 0.0315% | $84.59 | $1.63M | -0.21% | |
| 2026-01-23 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 13,151 0.0209% | $82.42 | $1.08M | -0.21% | |
| 2026-01-20 | Sale | PATEL DINESH V PH D | President and CEO | 34,438 0.0545% | $82.48 | $2.84M | -0.38% | |
| 2026-01-20 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 9,514 0.015% | $82.48 | $784,715 | -0.38% | |
| 2026-01-20 | Sale | Ali Asif | Chief Financial Officer | 8,588 0.0136% | $82.48 | $708,338 | -0.38% | |
| 2025-11-17 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 2,712 0.0043% | $84.77 | $229,896 | +0.54% | |
| 2025-10-10 | Sale | Waddill William D. | director | 12,000 0.0181% | $81.62 | $979,480 | -3.57% | |
| 2025-09-22 | Sale | Waddill William D. | director | 4,000 0.0064% | $64.25 | $257,000 | +29.02% | |
| 2025-08-27 | Sale | Waddill William D. | director | 4,000 0.0062% | $59.25 | $237,000 | +32.77% | |
| 2025-07-25 | Sale | PATEL DINESH V PH D | President and CEO | 10,415 0.0167% | $54.78 | $570,534 | +41.21% | |
| 2025-07-23 | Sale | PATEL DINESH V PH D | President and CEO | 17,520 0.0286% | $54.79 | $959,921 | +43.66% | |
| 2025-07-22 | Sale | PATEL DINESH V PH D | President and CEO | 22,065 0.0356% | $55.05 | $1.21M | +41.42% | |
| 2025-07-21 | Sale | PATEL DINESH V PH D | President and CEO | 12,859 0.0206% | $54.86 | $705,445 | +40.67% | |
| 2025-06-10 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 10,000 0.0163% | $57.03 | $570,300 | +19.27% | |
| 2025-06-09 | Sale | MOLINA ARTURO MD | Chief Medical Officer | 10,000 0.0161% | $55.51 | $555,100 | +20.40% |
| PATEL DINESH V PH D | President and CEO | 574505 0.919% | $48.54M | 1 | 22 | +243.28% |
| MOLINA ARTURO MD | Chief Medical Officer | 84115 0.1346% | $7.11M | 0 | 13 | |
| Ali Asif | Chief Financial Officer | 60320 0.0965% | $5.1M | 0 | 9 | |
| Waddill William D. | director | 5130 0.0082% | $433,433.70 | 0 | 8 | |
| Papanek Julie | director | 2453255 3.9242% | $207.28M | 1 | 0 | +18.24% |
| JOHNSON & JOHNSON | 10 percent owner | 2449183 3.9177% | $206.93M | 1 | 0 | +18.24% |
| CANAAN X L.P. | 10 percent owner | 2116552 3.3856% | $178.83M | 1 | 13 | +18.24% |
| Shanafelt Armen | 2099482 3.3583% | $177.39M | 1 | 0 | +18.24% | |
| LV Management Group, LLC | 10 percent owner | 2099482 3.3583% | $177.39M | 1 | 0 | +18.24% |
| Gupta Suneel | Chief Development Officer | 266983 0.4271% | $22.56M | 1 | 3 | +243.28% |
| Liu David Y | Chief Scientific Officer | 58254 0.0932% | $4.92M | 0 | 12 | |
| Shames Richard S. | Chief Medical Officer | 32021 0.0512% | $2.71M | 0 | 6 | |
| SELICK HAROLD E | director | 15310 0.0245% | $1.29M | 1 | 0 | +198.8% |
| Giraudo Bryan | director | 8000 0.0128% | $675,920.00 | 2 | 0 | +243.28% |
| Kalkofen Donald A. | Chief Financial Officer | 1175 0.0019% | $99,275.75 | 1 | 0 | +243.28% |
| KHOSLA CHAITAN PHD | director | 0 0% | $0 | 0 | 1 | |
| O'Neil Thomas P. | Chief Financial Officer | 0 0% | $0 | 0 | 1 | |
| Noonberg Sarah B. | director | 0 0% | $0 | 0 | 2 |
$159,914,414 | 243 | 18.52% | $4.29B | |
$193,151,375 | 134 | 8.18% | $4.49B | |
$224,382,625 | 44 | 27.62% | $5.19B | |
$477,065,869 | 34 | 82.05% | $5.45B | |
$103,944,213 | 17 | 5.95% | $6.91B | |
$74,605,681 | 14 | 47.06% | $4.64B | |
$57,686,748 | 13 | 21.11% | $6B | |
$75,296,863 | 13 | 33.79% | $6.28B | |
$9,976,473 | 12 | 29.52% | $6.76B | |
$91,269,919 | 12 | 12.86% | $4.64B | |
$2,477,801 | 11 | 4.98% | $5.76B | |
$3,073,199 | 10 | 16.77% | $4.94B | |
Protagonist Therapeutics, Inc. (PTGX) | $35,908,794 | 10 | 126.31% | $5.28B |
$20,499,451 | 9 | 71.54% | $5.64B | |
$25,064,843 | 9 | 12.75% | $4.86B | |
$55,713,031 | 8 | -0.36% | $5.96B | |
$2,246,813 | 6 | 70.15% | $4.58B | |
$105,414,951 | 5 | 10.07% | $7.53B | |
$7,600,000 | 1 | -4.05% | $4.06B |
| Increased Positions | 148 | +45.96% | 9M | +13.36% |
| Decreased Positions | 142 | -44.1% | 7M | -10.09% |
| New Positions | 52 | New | 3M | New |
| Sold Out Positions | 37 | Sold Out | 2M | Sold Out |
| Total Postitions | 328 | +1.86% | 73M | +3.27% |
| Blackrock, Inc. | $819,861.00 | 14.93% | 9.4M | -226,109 | -2.35% | 2025-09-30 |
| Farallon Capital Management Llc | $540,168.00 | 9.84% | 6.2M | +24,000 | +0.39% | 2025-09-30 |
| Rtw Investments, Lp | $501,832.00 | 9.14% | 5.76M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $371,145.00 | 6.76% | 4.26M | -101,366 | -2.33% | 2025-09-30 |
| State Street Corp | $275,994.00 | 5.03% | 3.17M | -41,748 | -1.3% | 2025-09-30 |
| Bvf Inc/Il | $223,261.00 | 4.07% | 2.56M | -650,125 | -20.25% | 2025-09-30 |
| Johnson & Johnson | $213,520.00 | 3.89% | 2.45M | 0 | 0% | 2025-09-30 |
| Wellington Management Group Llp | $166,378.00 | 3.03% | 1.91M | +870,708 | +83.9% | 2025-09-30 |
| Ubs Group Ag | $165,294.00 | 3.01% | 1.9M | -605,243 | -24.2% | 2025-09-30 |
| Deep Track Capital, Lp | $149,574.00 | 2.72% | 1.72M | -2M | -47.14% | 2025-09-30 |